For the quarter ending 2025-09-30, RMTI had $1,128K increase in cash & cash equivalents over the period. -$1,536K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -4,760 | - |
| Depreciation and amortization | 544 | 1,102 |
| Stock-based compensation | 532 | 827 |
| Write-off of inventory | 0 | 178 |
| Change in inventory reserves | -61 | - |
| Non-cash lease expense from right of use assets | 525 | 1,091 |
| Amortization of debt financing costs and accretion of debt discount and premium | 89 | 176 |
| Loss on disposal of assets | 1 | -57 |
| Realized gain on sale of investments | 181 | - |
| Gain on rou early terminations | 24 | - |
| Accounts receivable | 244 | -207 |
| Inventory | -257 | -1,618 |
| Prepaid and other assets | 573 | -1,043 |
| Accounts payable | 23 | -1,367 |
| Lease liabilities | -421 | -808 |
| Accrued and other liabilities | -139 | -2,165 |
| Deferred license revenue | 0 | -475 |
| Net cash (used in) provided by operating activities | -1,307 | -1,643 |
| Purchases of investments available-for-sale | 7,080 | 5,877 |
| Proceeds from sales of investments available-for-sale | 3,000 | 6,000 |
| Purchases of equipment | 229 | 227 |
| Net cash used in investing activities | -4,309 | -104 |
| Payments on insurance financing note payable | 198 | 268 |
| Payments on financing lease liabilities | 124 | 294 |
| Proceeds from issuance of common stock | 7,816 | 0 |
| Deferred consideration paid in connection with evoqua asset acquisition | 750 | 871 |
| Net cash provided by financing activities | 6,744 | -1,433 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0 |
| Net (decrease) increase in cash and cash equivalents | 1,128 | -3,180 |
| Cash and cash equivalents at beginning of period | 15,662 | - |
| Cash and cash equivalents at end of period | 13,610 | - |
ROCKWELL MEDICAL, INC. (RMTI)
ROCKWELL MEDICAL, INC. (RMTI)